Phase II trial of polysialylated erythropoietin (ErepoXen) in patients with chronic kidney disease and not on dialysis.
Latest Information Update: 27 Nov 2014
Price :
$35 *
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Anaemia
- Focus Adverse reactions
- 27 Nov 2014 New trial record